Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Matthew Foy currently holds 1,183,663 shares of Decibel Therapeutics, Inc. (DBTX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Matthew Foy has been a net buyer of DBTX stock. They have purchased $2.7M and sold $0 worth of shares.
Matthew Foy's most recent insider trade was on Feb 17, 2021, when they purchased 150,000 shares at $18.00 per share.
Matthew Foy serves as Executive at Decibel Therapeutics, Inc. (DBTX). They have executed 4 insider transactions totaling $2.7M over their tenure at the company.
Matthew Foy holds the position of Executive at Decibel Therapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 5 years and currently hold a stake valued at $0.
Matthew Foy has shown a buying trading pattern, with $2.7M in total purchases and $0 in total sales across all transactions. Their most recent activity indicates a tendency to accumulate shares.
The largest transaction by Matthew Foy was on Feb 17, 2021, when they purchased $2.7M worth of DBTX shares. This transaction involved 150,000 shares at $18.00 per share.
Matthew Foy currently owns 1,183,663 shares of Decibel Therapeutics, Inc. (DBTX), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Matthew Foy's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Matthew Foy has 4 Form 4 filings on record as an insider at Decibel Therapeutics, Inc..
Set alerts for Matthew Foy and 40,000+ other insiders.